This is Why Cannabis Science inc Is Bottoming Out
Connect with us

CBD Stocks

Why Cannabis Science Inc (OTCMKTS:CBIS) Is Bottoming Out

Published

on

Cannabis Science

Shares of Cannabis Science Inc (OTCMKTS: CBIS) are looking to bottom out, from one-year lows, after a rollercoaster first quarter. The stock has had to contend with wild swings since the start of the year.

After starting the year on a roll and rallying by more than 50%, the stock did succumb to bearish pressure consequently plunging to the $0.03 level.

CBIS Catalysts And Price Analysis

With the stock having taken out the $0.04 level, it might as well have hit the floor and due for a correction higher as a bounce-back play. Some of the catalysts triggering a rally from current lows is the confirmation that the company is expanding its footprint into Canada.

In the recent past, the company has also confirmed the formation iCannabinoid Ambassadors Program. The program is geared towards expanding the company’s footprint and supporting the development of initiatives into new markets.

Cannabis Science has also confirmed plans to expand the scope of its sponsored research in Nigeria to address the potential use of CBD to treat neurological conditions such as Post Traumatic Disorder.

A bounce back from the $0.03 level could as well signal revitalized investors sentiments in the wake of recent developments. After the recent bounce back, the $0.05 is the immediate resistance level standing in the way of the stock edging higher from current lows.

CBIS Daily Chart

Cannabis Science needs to rally and find support above the $0.05 mark if it is to stay on track to correct higher after crashing in recent months. For the stock to turn bullish as a long-term play then it will have to rally and takeout the $0.06 resistance level.

What Does Cannabis Science Do?

Cannabis Science with its subsidiaries is engaged in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. The company is currently working on cannabis-infused products for addressing autism, blood pressure as well as cancer among other illnesses.

Canada Expansion

Shares of Cannabis Sciences have started bottoming out on the company announcing plans to expand into Canada in pursuit of opportunities for growth. The company has since confirmed the formation of Cannabis Science Canada, a wholly-owned subsidiary, tasked with pursuing opportunities in Canada.

With the new subsidiary in place, the company has already begun negotiations for Canadian land where it plans to launch cannabis cultivation and production operations. The company is also pursuing relevant licenses.

“We currently have a number of very important research and drug-development initiatives underway in the U.S., Europe, South America, and in Sub-Saharan Africa. As we expand into Canada, the Company can leverage these opportunities in order to rapidly grow our business model in Canada and begin releasing our exciting product lines,” stated CEO Raymond Dabney.

Dabney expects Canada to be an important market for Cannabis Science in the wake of recreational use legalization. In addition to selling cannabis products, the company is also planning to engage in cannabis research and drug development activities.

iCannabinoid Ambassador Program

Expansion into Canada is not the only thing working for Cannabis Science. The company has since confirmed the formation of iCannabinoid Ambassador Program whose members are tasked with the responsibility of expanding the company’s footprint into new markets.

Each ambassador under the new program will be designated an area of interest and expertise to help educate the public about the company’s initiatives. The core objective with the new program is to take advantage of the consortium of partnerships and licensing programs for patents as well as other product development initiatives.

Patent Licensing

Cannabis Sciences has already opened discussions as it seeks to license its U.S Patent for the composition of cannabinol for treatment of various Neurobehavioral Disorders including sleep disorder and PTSD.

“There are so many products we are developing for current market conditions for sleep deprivation, anxiety, PTSD, and many more neurological conditions. […]Our formulations, product testing, and manufacturing and packaging will be split between several facilities in the United States and Canada,” added Mr. Dabney.

Bottom Line

Cannabis Science has had to contend wild price swings in recent months after starting the year on a roll and then coming under pressure. Recent price action activity indicates that the stock has hit bottom and due for a correction higher.

The company has already served a number of catalysts starting with the expansion into Canada as well as plans to develop new CBD therapies for addressing various medical conditions that continue to prop market sentiments.

For those looking for a bounce-back play with a good risk/reward setup, CBIS is worth a look.

For the latest updates on CBIS and other CBD stocks, sign up below!

Disclosure: We have no position in CBIS and have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

CBD Stocks

Charlotte’s Web Stock (TSE:CWEB) (OTCMKTS:CWBHF) Poised For Breakout And Here’s Why

Published

on

Charlotte's Web Stock

Charlotte’s Web Stock (TSE:CWEB) (OTCMKTS:CWBHF) is currently at one of its lowest price levels in about five months. That is the result of a selloff that kicked off toward late September after the stock reached one of its highest watermarks at $23 in August.

You cannot rule out profit-taking as having contributed to the decline that has brought the stock to its current lows considering the stock pulled up from one of its lowest levels this year in July before the August breakout. A repeat of the August bull run that powered CWBHF to one of its highest price levels this year seems to be in the offing.

Firstly, after a string of declines for much of last week and early this week, CWBHF has begun showing signs of a comeback. The stock closed the last session (November 5), up. Now the stock has found immediate support at $10.9 from where it looks set for a powerful breakout as happened in March, June, and July.

In March, for instance, CWBHF bolted from a low of $13 on March 8 to reach its one-year peak of $25 in a space of fewer than 30 days on April 4. Profit-taking kicked off after that and the stock fell to around $10 in mid-June, from where it began rising again, topping $18.5 in early July. Investors again took profit and toward late July the stock was back down at around $13.5.…

Continue Reading

CBD Stocks

CV Sciences, Inc. (OTCMKTS:CVSI): You Don’t Want To Miss This Bounce Back

Published

on

OTCMKTS:CVSI

CV Sciences, Inc. (OTCMKTS:CVSI) is currently trading at one of its lowest price points in about a year. The decline that has taken the stock to its current lows began unfolding in mid-September.

By late September, CVSI had lost so much ground that the stock was trading below $1.60. However, it again began moving up and in early October the stock had climbed back up enough to flirt with $2.60. From that level, CVSI retreated and by mid-October it was doing rounds at about $1.85. The stock began climbing back up again and toward late October it was trading well above $2. But in late October until now it has begun pulling back again, closing down in three of the last five trading sessions.

Looking at the charts, you cannot dispute that CVSI has demonstrated a pattern that investors can take advantage of to profit from the stock in short-terms. After rallying, CVSI tends to pull back, thereby allowing investors who may have missed its previous bull run to get on board before it begins another flight. Therefore, you shouldn’t be surprised if CVSI sharply reverses course and begins trending up from current levels.

About OTCMKTS:CVSI

CVSI is a hemp CBD company that makes products for both consumer and therapeutics markets. The company operates production facilities that follow good manufacturing practices. Its PlusCBD Oil product has been noted as the top-selling hemp CBD brand.

Continue Reading

CBD Stocks

Baristas Coffee Company Inc (OTCMKTS:BCCI) Breaks Out: What’s Driving The Stock This Time?

Published

on

OTCMKTS:BCCI

For more than four months, Baristas Coffee Company Inc (OTCMKTS:BCCI) struggled to trade above $0.0186 following a short-live breakout in June. However, a bull run that began in late August, interrupted by some profit taking in September, has powered Baristas to its highest watermark since May.

While Baristas might pull back a bit from its latest peak as some investors move to book profits, the stock should find support at $0.015.

A pullback from the latest high should open the door to investors who missed the initial bull run to get in, pushing the stock to even greater highs. Meanwhile, short-sellers will be scrambling to cover their short positions in Baristas as surges, and that would fuel further rally in the stock.

However, if Baristas drops below its critical support level of $0.015, then that could leave it susceptible to fresh short-seller attacks, which could in turn push the stock even lower.

Baristas has recently entered into commercial partnerships that should provide some catalytic effect for the stock.

About OTCMKTS:BCCI

Baristas Coffee Company has been around since 1996. It launched Innovative Communications but later rebranded to its current name in 2010.

The company operates as a specialty drive-through beverage retailer, mostly focused on coffee drinks. Baristas prides itself as the leading white coffee brand in the US. Additionally, Baristas also sells pastries and confections. True to its roots as an innovative business, Baristas has found…

Continue Reading

Enter Symbol For Report



MJ Stocks